Roche’s Giredestrant Shows Significant Progression-Free Survival Benefit in Phase III ER-Positive Breast Cancer Trial Read more
FDA Grants Breakthrough Therapy Designation to Raludotatug Deruxtecan for CDH6-Positive Platinum-Resistant Ovarian and Related Cancers Read more
Novartis to Acquire Tourmaline Bio, Boosting Cardiovascular Pipeline with Pacibekitug for ASCVD Treatment Read more